(Q44050418)

English

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

scientific article published on 7 March 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Wai Kin D Ko

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Elsa Pioli

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Qin Li

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Steve McGuire

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Audrey Dufour

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Todd B Sherer

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Maurizio F Facheris

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

7 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

772-779

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Molecular mechanisms underlying levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Amantadine inhibits NMDA receptors by accelerating channel closure during channel block.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Amantadine-induced coma

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25859

21 January 2018

Identifiers

10.1002/MDS.25859

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44050418&oldid=2106014544"